The immunomodulatory drug fingolimod (FTY720, Gilenya R) was approved for oral
treatment of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good …

Abstract Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase that
regulates many cellular processes. Given the central role of PP2A in regulating diverse …

Cancer, more than any other human disease, now has a surfeit of potential molecular targets
poised for therapeutic exploitation. Currently, a number of attractive and validated cancer …

Inflammatory gastrointestinal (GI) diseases and malignancies are associated with growing
morbidity and cancer-related mortality worldwide. GI tumor and inflammatory cells contain …

The serine/threonine phosphatase PP2A regulates a vast portion of the phosphoproteome
including pathways involved in apoptosis, proliferation and DNA damage response and …

Aberrant activation of signal transduction pathways can transform a normal cell to a
malignant one and can impart survival properties that render cancer cells resistant to …

FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple
sclerosis that sequesters T-cells to lymph nodes through functional antagonism of …

Neurodevelopmental disorders (NDDs), including intellectual disability (ID), autism and
schizophrenia, have high socioeconomic impact, yet poorly understood etiologies. A recent …

Abstract Protein phosphatase 2A (PP2A) is a highly complex heterotrimeric enzyme that
catalyzes the selective removal of phosphate groups from protein serine and threonine …

Sphingolipids are an extensive class of lipids with different functions in the cell, ranging from
proliferation to cell death. Sphingolipids are modified in multiple cancers and are …